A new French biotech investment house has been launched with a €200m institutional investor-backed fund.
Jeito Capital has been created by Rafaèle Tordjman, who previously spent 16 years with VC house Sofinnova Partners, ultimately as co-leader and partner.
The firm’s capital will be used to support about 15 drug start-ups it believes have the potential to become future market leaders, helping them accelerate the development and marketing of vital innovations in therapeutic areas with high medical needs.
Tordjman said, “The undertaking of Jeito Capital is coming to fruition at a time when the industry recognizes a need to support breakthrough innovation.
“Our goal is to support start-ups growth destined to become the market leaders of tomorrow, as well as to serve our three targets – patients, entrepreneurs and investors who place their trust in us.”
Paris-based Jeito, which also has a presence in the US, will primarily have a European sourcing strategy with consideration for marketing in America.
Copyright © 2020 AltAssets